STOCKHOLM, Sweden--(BUSINESS WIRE)--Amgen (Europe) GmbH today announced results from the Evaluation of the Clinical Use of Mimpara in Haemodialysis and Peritoneal Dialysis Patients, an Observational Study (ECHO) at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) congress. Data show that a higher percentage of dialysis patients with secondary hyperparathyroidism (SHPT) achieved and maintained National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQITM) targets with Mimpara® (cinacalcet), compared to their previous treatment (vitamin D sterols and phosphate binders). In addition, data also show that Mimpara effectively controls SHPT regardless of whether patients were receiving concomitant vitamin D.
